Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (108)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (277)
  2. Genitourinary Oncology Service (277)
  3. Solid Tumor Oncology Division (277)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Department of Pathology and Laboratory Medicine (43)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (13)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (17)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (25)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (277)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350)
    Meeting Abstract

    Subudhi, S. K.; Aparicio, A.; Zurita, A. J.; Doger, B.; Kelly, W. K.; Peer, A.; Rathkopf, D. E.; Karsh, L. I.; Tryon, J. J.; Kothari, N.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration resistant prostate cancer
    Meeting Abstract

    Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Bilen, M. A.; Rosen, L. S.; Gottardis, M.; Infante, J. R.; Adams, B. J.; Liu, L.; Theuer, C. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes
    Meeting Abstract

    Mota, J. M.; Barnett, E.; Nauseef, J.; Stopsack, K. H.; Wibmer, A. G.; Danila, D. C.; Rathkopf, D. E.; Slovin, S. F.; Kantoff, P. W.; Scher, H. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Paller, C. J.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W. D.; Den, R. B.; Deville, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Human prostate cancer immune phenotypes after androgen deprivation therapy
    Meeting Abstract

    Dallos, M.; Obradovic, A.; Chowdhury, N.; Bujanda, Z. L.; Aggen, D. H.; Hawley, J.; Rathkopf, D. E.; Drake, C. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations
    Meeting Abstract

    Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer
    Meeting Abstract

    Zhang, Z.; Karthaus, W.; Mota, J. M.; Mu, P.; Wu, C.; Abida, W.; Linton, E.; Lee, Y. S.; Lee, E.; Mao, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save